Advertisement
The Company plans to announce 12-month data from the SYNTAX trial, whichcompares percutaneous coronary intervention (PCI) using the TAXUS(R)Express2(TM) Paclitaxel-Eluting Coronary Stent System to coronary arterybypass graft (CABG) surgery in the most complex patient groups.
Advertisement
"SYNTAX is a landmark study that will provide the medical community thefirst and only critical data from a randomized clinical trial related tocomplex patients with left main and three vessel disease treated with drug-eluting stents (DES)," said Keith D. Dawkins, M.D., Senior Vice President andAssociate Chief Medical Officer at Boston Scientific. "The patients recruitedin SYNTAX have exceptionally complex anatomy and advanced disease. Thisunique population would typically be treated with CABG and represents the mostchallenging group ever studied in a DES trial. SYNTAX will expand the body ofknowledge of PCI use and help inform physicians as to appropriate treatmentoptions for the sickest patients."
-- SYNTAX Study data. One-year outcomes data from the SYNTAX trial willbe presented by Patrick W. Serruys, M.D., Ph.D., and Friedrich W. Mohr, M.D.,Ph.D., beginning at 11:18 a.m. in the Munich Room (Zone A4). The Companyplans to issue a press release at this time. SYNTAX is the first randomized,controlled clinical trial comparing PCI using drug-eluting stents to CABG inpatients with left main and/or three vessel disease. The presentation will bepart of an Interventional Cardiology Hot Line Session from 11:00 a.m. to 12:30p.m., chaired by William Wijns, M.D., and Petr Widimsky, M.D.
Tuesday, September 2
-- OLYMPIA Phases II and III data. One-year results from Phases II andIII of the global OLYMPIA registry will be presented by Oscar Mendiz, M.D., at12:15 p.m., in the Copenhagen Room (Zone B3). OLYMPIA is the world's largestprospective, multi-center, multi-phased registry for a single drug-elutingstent. The registry is designed to analyze real-world clinical outcomes datafor Boston Scientific's second-generation TAXUS(R) Liberte(R)Paclitaxel-Eluting Stent System. Results from more than 22,000 patients willfocus on safety and efficacy, and will highlight outcomes within thishigh-risk patient population. The Company plans to issue a press release atthis time.
-- Cardiac Rhythm Management Workshop. From 12:45-1:30 p.m., the Companywill sponsor a workshop session entitled "The continuing fight against suddendeath; patient selection and latest treatment enhancements," chaired byGuenter Breithardt, M.D., in the Bucharest Room (Zone A4). The workshop willinclude presentations from Silvia G. Priori, M.D., on "Simplifyingguideline-based patient selection," and by Michael Glikson, M.D., on"Improving patient benefits with new device technology."
-- Interventional Cardiology Symposium. From 2:00-3:30 p.m., the Companywill sponsor a satellite symposium entitled "Treatment algorithms in complexpatients -- What do the data support?" chaired by Keith D. Dawkins, M.D., andMarie-Claude Morice, M.D., in the Bucharest Room. The symposium will exploretreatment options for multi-vessel disease and left main disease withparticular focus on insights gained from the SYNTAX trial data.
Boston Scientific will present its latest innovations at booth B401 inExhibition Hall B2.
The safety and effectiveness of the TAXUS Express Stent has not beenestablished in patients with left main or three vessel disease. In the U.S.,the TAXUS Liberte Stent is an investigational device and is not available forsale.
About Boston Scientific
Boston Scientific is a worldwide developer, m
